| scholarly article | Q13442814 |
| P50 | author | Saïk Urien | Q41653760 |
| Jean-Marc Tréluyer | Q41653833 | ||
| P2093 | author name string | Jean-Marc Treluyer | |
| Déborah Hirt | |||
| Elodie Valade | |||
| Emmanuelle Pannier | |||
| Floris Fauchet | |||
| Saik Urien | |||
| Frantz Foissac | |||
| Sihem Benaboud | |||
| Ghislaine Firtion | |||
| Naim Bouazza | |||
| P2860 | cites work | Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group | Q28239283 |
| Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir | Q28345258 | ||
| Likelihood based approaches to handling data below the quantification limit using NONMEM VI. | Q31169718 | ||
| Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men. | Q33821263 | ||
| Is intrapartum intravenous zidovudine for prevention of mother-to-child HIV-1 transmission still useful in the combination antiretroviral therapy era? | Q34752077 | ||
| Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients | Q35065817 | ||
| Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. | Q35138883 | ||
| Pharmacokinetics and virological efficacy after switch to once-daily lopinavir-ritonavir in treatment-experienced HIV-1-infected children | Q35191590 | ||
| Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. | Q37245017 | ||
| Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children | Q37263890 | ||
| Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1 | Q40469287 | ||
| High exposure to zidovudine during the first 2 weeks of life and concentration-toxicity relationships | Q42271522 | ||
| Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine + optional lamivudine in pregnancy and prevention of vertical HIV transmission | Q42681152 | ||
| A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults | Q43580186 | ||
| Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children | Q44343579 | ||
| Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose | Q44470467 | ||
| Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type 1-infected women and newborn infants | Q45746364 | ||
| Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring | Q45753331 | ||
| Maternal and umbilical cord serum zidovudine levels in human immunodeficiency virus infection | Q45753600 | ||
| The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudi | Q45779956 | ||
| Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum | Q46052812 | ||
| Quantification of seven nucleoside/nucleotide reverse transcriptase inhibitors in human plasma by high-performance liquid chromatography with tandem mass-spectrometry | Q46714425 | ||
| Pharmacokinetics of lamivudine, zidovudine, and nevirapine administered as a fixed-dose combination formulation versus coadministration of the individual products | Q46930423 | ||
| Placental transfer of Zidovudine in first trimester of pregnancy | Q58029532 | ||
| Placental passage of azathiothymidine (AZT) during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound | Q67956898 | ||
| Pharmacokinetic disposition of zidovudine during pregnancy | Q68184172 | ||
| Fetoplacental passage of zidovudine | Q69372251 | ||
| The pharmacokinetics of zidovudine administered by continuous infusion in children | Q69483859 | ||
| Variability in zidovudine serum concentrations | Q71842941 | ||
| Pharmacokinetic and toxicity studies of AZT (zidovudine) following perfusion of human term placenta for 14 hours | Q73162748 | ||
| Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children | Q80988077 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | zidovudine | Q198504 |
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | 1387-1396 | |
| P577 | publication date | 2014-12-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: too high dose infused at labour? | |
| P478 | volume | 78 |
| Q26738453 | Management of HIV Infection during Pregnancy in the United States: Updated Evidence-Based Recommendations and Future Potential Practices | cites work | P2860 |
Search more.